参考文献/References:
[1] 邸金娜,刘敬禹,张莉.基于网络药理及分子对接技术对人参治疗非小细胞肺癌作用机制研究[J].陕西医学杂志,2021,50(6):669-672,677.
[2] 赵鹏,刘冬,兰飞,等.非小细胞肺癌化疗前后血清糖类抗原125、基质金属蛋白酶-9、可溶性程序性死亡配体1水平变化及其与疗效关系研究[J].陕西医学杂志,2022,51(12):1564-1567.
[3] MORRISON M J,BORIACK-SJODIN P A,SWINGER K K,et al.Identification of a peptide inhibitor for the histone methyltransferase WHSC1[J].PLoS One,2018,13(5):e0197082.
[4] MORISHITA M,MEVIUS D,DI-LUCCIO E.In vitro histone lysine methylation by NSD1,NSD2/MMSET/WHSC1 and NSD3/WHSC1L[J].BMC Struct Biol,2014,14:25.
[5] LI W,TIAN W,YUAN G,et al.Molecular basis of nucleosomal H3K36 methylation by NSD methyltransferases[J].Nature,2021,590(7846):498-503.
[6] WANG X,YEH S,WU G,et al.Identification and characterization of a novel androgen receptor coregulator ARA267-alpha in prostate cancer cells[J].J Biol Chem,2001,276(44):40417-40423.
[7] TOYOKAWA G,CHO H S,MASUDA K,et al.Histone lysine methyltransferase Wolf-Hirschhorn syndrome candidate 1 is involved in human carcinogenesis through regulation of the Wnt pathway[J].Neoplasia,2011,13(10):887-898.
[8] GONZALEZ-PECCHI V,KWAN A K,DOYLE S,et al.NSD3S stabilizes MYC through hindering its interaction with FBXW7[J].J Mol Cell Biol,2020,12(6):438-447.
[9] YUAN G,FLORES N M,HAUSMANN S,et al.Elevated NSD3 histone methylation activity drives squamous cell lung cancer[J].Nature,2021,590(7846):504-508.
[10] JAFFE J D,WANG Y,CHAN H M,et al.Global chromatin profiling reveals NSD2 mutations in pediatric acute lymphoblastic leukemia[J].Nat Genet,2013,45(11):1386-1391.
[11] LAURING J,ABUKHDEIR A M,KONISHI H,et al.The multiple myeloma associated MMSET gene contributes to cellular adhesion,clonogenic growth,and tumorigenicity[J].Blood,2008,111(2):856-864.
[12] JEONG G Y,PARK M K,CHOI H J,et al.NSD3-induced methylation of H3K36 activates NOTCH signaling to drive breast tumor initiation and metastatic progression[J].Cancer Res,2021,81(1):77-90.
[13] SUN Y,XIE J,CAI S,et al.Elevated expression of nuclear receptor-binding SET domain 3 promotes pancreatic cancer cell growth[J].Cell Death Dis,2021,12(10):913.
[14] YUAN S,NATESAN R,SANCHEZ-RIVERA F J,et al.Global regulation of the histone mark H3K36me2 underlies epithelial plasticity and metastatic progression[J].Cancer Discov,2020,10(6):854-871.
[15] EZPONDA T,POPOVIC R,SHAH M Y,et al.The histone methyltransferase MMSET/WHSC1 activates TWIST1 to promote an epithelial-mesenchymal transition and invasive properties of prostate cancer[J].Oncogene,2013,32(23):2882-2890.
[16] CHEONG C M,MROZIK K M,HEWETT D R,et al.Twist-1 is upregulated by NSD2 and contributes to tumour dissemination and an epithelial-mesenchymal transition-like gene expression signature in t(4; 14)-positive multiple myeloma[J].Cancer Lett,2020,475:99-108.
[17] YI L,YI L,LIU Q,et al.Downregulation of NSD3(WHSC1L1)inhibits cell proliferation and migration via ERK1/2 deactivation and decreasing CAPG expression in colorectal cancer cells[J].Onco Targets Ther,2019,12:3933-3943.
[18] XUE W,SHEN Z,LI L,et al.Long non-coding RNAs MACC1-AS1 and FOXD2-AS1 mediate NSD2-induced cisplatin resistance in esophageal squamous cell carcinoma[J].Mol Ther Nucleic Acids,2021,23:592-602.
[19] HE C,LIU C,WANG L,et al.Histone methyltransferase NSD2 regulates apoptosis and chemosensitivity in osteosarcoma[J].Cell Death Dis,2019,10(2):65.
[20] WANG J J,ZOU J X,WANG H,et al.Histone methyltransferase NSD2 mediates the survival and invasion of triple-negative breast cancer cells via stimulating ADAM9-EGFR-AKT signaling[J].Acta Pharmacol Sin,2019,40(8):1067-1075.
[21] WANG Y,ZHU L,GUO M,et al.Histone methyltransferase WHSC1 inhibits colorectal cancer cell apoptosis via targeting anti-apoptotic BCL2[J].Cell Death Discov,2021,7(1):19.
[22] DROSOS Y,MYERS J A,XU B,et al.NSD1 mediates antagonism between SWI/SNF and polycomb complexes and is required for transcriptional activation upon EZH2 inhibition[J].Mol Cell,2022,82(13):2472-2489.
[23] SUN Z,LIN Y,ISLAM M T,et al.Chromatin regulation of transcriptional enhancers and cell fate by the Sotos syndrome gene NSD1[J].Mol Cell,2023,83(14):2398-2416.
[24] STABERG M,RASMUSSEN R D,MICHAELSEN S R,et al.Targeting glioma stem-like cell survival and chemoresistance through inhibition of lysine-specific histone demethylase KDM2B[J].Mol Oncol,2018,12(3):406-420.
[25] SANCHES J,SONG B,ZHANG Q,et al.The role of KDM2B and EZH2 in regulating the stemness in colorectal cancer through the PI3K/AKT pathway[J].Front Oncol,2021,11:637298.
[26] LI Y,GOLDBERG E M,CHEN X,et al.Histone methylation antagonism drives tumor immune evasion in squamous cell carcinomas[J].Mol Cell,2022,82(20):3901-3918.
[27] GARCíA-CARPIZO V,SARMENTERO J,HAN B,et al.NSD2 contributes to oncogenic RAS-driven transcription in lung cancer cells through long-range epigenetic activation[J].Sci Rep,2016,6:32952.
[28] SENGUPTA D,ZENG L,LI Y,et al.NSD2 dimethylation at H3K36 promotes lung adenocarcinoma pathogenesis[J].Mol Cell,2021,81(21):4481-4492.
[29] SATPATHY S,KRUG K,JEAN BELTRAN P M,et al.A proteogenomic portrait of lung squamous cell carcinoma[J].Cell,2021,184(16):4348-4371.
[30] XU D,LIU S,WU X,et al.Dissecting the immunological profiles in NSD3-Amplified LUSC through integrative multi-scale analyses[J].Cancers(Basel),2022,14(20):4997.
[31] TU Z,CHEN X,TIAN T,et al.Prognostic significance of epigenetic regulatory gene expression in patients with non-small-cell lung cancer[J].Aging(Albany NY),2021,13(5):7397-7415.
[32] DI-LUCCIO E.Inhibition of nuclear receptor binding SET domain 2/Multiple myeloma SET domain by LEM-06 implication for epigenetic cancer therapies[J].J Cancer Prev,2015,20(2):113-120.
[33] SHEN Y,MORISHITA M,LEE D,et al.Identification of LEM-14 inhibitor of the oncoprotein NSD2[J].Biochem Biophys Res Commun,2019,508(1):102-108.
[34] COUSSENS N P,KALES S C,HENDERSON M J,et al.High-throughput screening with nucleosome substrate identifies small-molecule inhibitors of the human histone lysine methyltransferase NSD2[J].J Biol Chem,2018,293(35):13750-13765.
[35] HUANG H,HOWARD C A,ZARI S,et al.Covalent inhibition of NSD1 histone methyltransferase[J].Nat Chem Biol,2020,16(12):1403-1410.
[36] DILWORTH D,HANLEY R P,FERREIRA DE-FREITAS R,et al.A chemical probe targeting the PWWP domain alters NSD2 nucleolar localization[J].Nat Chem Biol,2022,18(1):56-63.
[37] BöTTCHER J,DILWORTH D,REISER U,et al.Fragment-based discovery of a chemical probe for the PWWP1 domain of NSD3[J].Nat Chem Biol,2019,15(8):822-829.
[38] XU C,MENG F,PARK K S,et al.A NSD3-targeted PROTAC suppresses NSD3 and cMyc oncogenic nodes in cancer cells[J].Cell Chem Biol,2022,29(3):386-397.
相似文献/References:
[1]王晓东,景鹏宇△,崔 凯,等.术前外周血中性粒细胞淋巴细胞比值对ⅠⅢ期非小细胞肺癌患者预后的影响[J].陕西医学杂志,2019,(12):1612.
[2]彭 峰,彭奕华,张宏华,等.非小细胞肺癌化疗前后血清糖类抗原125、肿瘤异常蛋白水平变化及其与疗效的关系[J].陕西医学杂志,2020,49(7):851.[doi:DOI:10.3969/j.issn.10007377.2020.07.023]
PENG Feng,PENG Yihua,ZHANG Honghua,et al.Changes of serum CA125 and TAP levels before and after chemotherapy for non-small cell lung cancer and their relationship with curative effect[J].,2020,49(4):851.[doi:DOI:10.3969/j.issn.10007377.2020.07.023]
[3]杨 昕,刘 芳,杜 静,等.肺癌癌组织中过氧化物酶增殖体激活受体γ基因表达水平对培美曲塞化疗疗效的预测价值*[J].陕西医学杂志,2020,49(10):1359.[doi:DOI:10.3969/j.issn.1000-7377.2020.10.042]
YANG Xin,LIU Fang,DU Jing,et al.Predictive value of PPARγ gene expression level in lung cancer tissue for curative effect of pemetrexed chemotherapy[J].,2020,49(4):1359.[doi:DOI:10.3969/j.issn.1000-7377.2020.10.042]
[4]王晓东,吕 峰△,崔 凯.ⅢA-N2期非小细胞肺癌纵隔淋巴结跳跃性转移临床特点及对预后的影响[J].陕西医学杂志,2020,49(12):1634.[doi:DOI:10.3969/j.issn.1000-7377.2020.12.025]
[5]苏艳丽,李 波.Th9细胞对非小细胞肺癌患者CD8+T细胞抗肿瘤活性的调控作用[J].陕西医学杂志,2021,50(1):15.[doi:DOI:10.3969/j.issn.1000-7377.2021.01.004]
SU Yanli,LI Bo.Regulatory of Th9 cells on anti-tumor activity of CD8+T cells in patients with non-small-cell lung cancer[J].,2021,50(4):15.[doi:DOI:10.3969/j.issn.1000-7377.2021.01.004]
[6]岳 英,董锦华,肖月梅.肺免疫微环境中调节因子表达对肿瘤生长和转移的影响[J].陕西医学杂志,2021,50(4):495.[doi:DOI:10.3969/j.issn.1000-7377.2021.04.030]
[7]崔 凯,白峻峰,支亚男,等.外泌体微小RNA-23a对非小细胞肺癌血管生成的影响及机制研究[J].陕西医学杂志,2021,50(9):1048.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.002]
CUI Kai,BAI Junfeng,ZHI Ya'nan,et al.Effect of exosome miR-23a on angiogenesis in NSCLC and its mechanism[J].,2021,50(4):1048.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.002]
[8]陈 彦,姜立朋.基于CT的影像组学特征对非小细胞肺癌放射治疗效果的评估价值[J].陕西医学杂志,2021,50(9):1094.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.013]
CHEN Yan,JIANG Lipeng.Evaluation value of CT-based imaging omics features for radiotherapy effect in treatment of non-small cell lung cancer[J].,2021,50(4):1094.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.013]
[9]崔 凯,支亚男,王壮壮,等.微小RNA-30对非小细胞肺癌侵袭、转移能力的影响及机制研究[J].陕西医学杂志,2021,50(10):1214.[doi:DOI:10.3969/j.issn.1000-7377.2021.10.009]
CUI Kai,ZHI Ya'nan,WANG Zhuangzhuang,et al.Effect and mechanism of miR-30 on invasion and metastasis of non-small cell lung cancer[J].,2021,50(4):1214.[doi:DOI:10.3969/j.issn.1000-7377.2021.10.009]
[10]梁乐乐,王 鹏,刘俊霞,等.非小细胞肺癌组织中T细胞免疫球蛋白区黏蛋白-3、程序性死亡因子-1及程序性因子配体1的表达分析[J].陕西医学杂志,2021,50(10):1227.[doi:DOI:10.3969/j.issn.1000-7377.2021.10.012]
LIANG Lele,WANG Peng,LIU Junxia,et al.Expression of TIM-3,PD-1 and PD-L1 in non-small cell lung cancer[J].,2021,50(4):1227.[doi:DOI:10.3969/j.issn.1000-7377.2021.10.012]